NYSE:BIO - Bio-Rad Laboratories, Inc. Class A Common Stock Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$296.76 -3.11 (-1.04 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$299.87
Today's Range$294.00 - $302.38
52-Week Range$208.95 - $304.36
Volume132,200 shs
Average Volume159,342 shs
Market Capitalization$8.98 billion
P/E Ratio72.38
Dividend YieldN/A
Beta1
Bio-Rad Laboratories, Inc. Class A Common Stock logoBio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:BIO
CUSIP09057220
Phone510-724-7000

Debt

Debt-to-Equity Ratio0.10
Current Ratio4.33
Quick Ratio2.99

Price-To-Earnings

Trailing P/E Ratio72.38
Forward P/E Ratio48.41
P/E Growth3.28

Sales & Book Value

Annual Sales$2.16 billion
Price / Sales4.09
Cash Flow$4.0730 per share
Price / Cash72.86
Book Value$98.38 per share
Price / Book3.02

Profitability

EPS (Most Recent Fiscal Year)$4.10
Net Income$122.24 million
Net Margins34.32%
Return on Equity3.84%
Return on Assets2.67%

Miscellaneous

Employees3,270
Outstanding Shares29,800,000

Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories, Inc. Class A Common Stock's stock symbol?

Bio-Rad Laboratories, Inc. Class A Common Stock trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories, Inc. Class A Common Stock's stock buyback program work?

Bio-Rad Laboratories, Inc. Class A Common Stock declared that its board has approved a share repurchase plan on Wednesday, November 29th 2017, which permits the company to buyback $250,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its shares are undervalued.

How were Bio-Rad Laboratories, Inc. Class A Common Stock's earnings last quarter?

Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) posted its quarterly earnings results on Tuesday, May, 8th. The medical research company reported $1.17 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.10. The medical research company earned $551.52 million during the quarter, compared to analyst estimates of $527.20 million. Bio-Rad Laboratories, Inc. Class A Common Stock had a net margin of 34.32% and a return on equity of 3.84%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $0.68 EPS. View Bio-Rad Laboratories, Inc. Class A Common Stock's Earnings History.

When is Bio-Rad Laboratories, Inc. Class A Common Stock's next earnings date?

Bio-Rad Laboratories, Inc. Class A Common Stock is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Bio-Rad Laboratories, Inc. Class A Common Stock.

What price target have analysts set for BIO?

5 Wall Street analysts have issued 12-month price objectives for Bio-Rad Laboratories, Inc. Class A Common Stock's shares. Their predictions range from $255.00 to $325.00. On average, they expect Bio-Rad Laboratories, Inc. Class A Common Stock's stock price to reach $298.75 in the next twelve months. View Analyst Ratings for Bio-Rad Laboratories, Inc. Class A Common Stock.

Who are some of Bio-Rad Laboratories, Inc. Class A Common Stock's key competitors?

Who are Bio-Rad Laboratories, Inc. Class A Common Stock's key executives?

Bio-Rad Laboratories, Inc. Class A Common Stock's management team includes the folowing people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 68)
  • Ms. Christine A. Tsingos, Exec. VP & CFO (Age 59)
  • Mr. John Goetz, Consultant (Age 68)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 62)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 56)

Has Bio-Rad Laboratories, Inc. Class A Common Stock been receiving favorable news coverage?

Media headlines about BIO stock have trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bio-Rad Laboratories, Inc. Class A Common Stock earned a news impact score of 0.19 on Accern's scale. They also gave news stories about the medical research company an impact score of 46.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Bio-Rad Laboratories, Inc. Class A Common Stock's major shareholders?

Bio-Rad Laboratories, Inc. Class A Common Stock's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.15%), Atlanta Capital Management Co. L L C (4.93%), American Century Companies Inc. (2.36%), Wells Fargo & Company MN (2.27%), Fort Washington Investment Advisors Inc. OH (1.05%) and Millennium Management LLC (0.92%). Company insiders that own Bio-Rad Laboratories, Inc. Class A Common Stock stock include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Institutional Ownership Trends for Bio-Rad Laboratories, Inc. Class A Common Stock.

Which major investors are selling Bio-Rad Laboratories, Inc. Class A Common Stock stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Clinton Group Inc., Citigroup Inc., Epoch Investment Partners Inc., WINTON GROUP Ltd, Spark Investment Management LLC, Fort Washington Investment Advisors Inc. OH and Polar Asset Management Partners Inc.. Company insiders that have sold Bio-Rad Laboratories, Inc. Class A Common Stock company stock in the last year include Christine A Tsingos, Giovanni Magni, James R Stark and Michael Crowley. View Insider Buying and Selling for Bio-Rad Laboratories, Inc. Class A Common Stock.

Which major investors are buying Bio-Rad Laboratories, Inc. Class A Common Stock stock?

BIO stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., Point72 Asset Management L.P., Amundi Pioneer Asset Management Inc., Westfield Capital Management Co. LP, Millennium Management LLC, Monarch Partners Asset Management LLC, Highland Capital Management LP and BlackRock Inc.. View Insider Buying and Selling for Bio-Rad Laboratories, Inc. Class A Common Stock.

How do I buy shares of Bio-Rad Laboratories, Inc. Class A Common Stock?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories, Inc. Class A Common Stock's stock price today?

One share of BIO stock can currently be purchased for approximately $296.76.

How big of a company is Bio-Rad Laboratories, Inc. Class A Common Stock?

Bio-Rad Laboratories, Inc. Class A Common Stock has a market capitalization of $8.98 billion and generates $2.16 billion in revenue each year. The medical research company earns $122.24 million in net income (profit) each year or $4.10 on an earnings per share basis. Bio-Rad Laboratories, Inc. Class A Common Stock employs 3,270 workers across the globe.

How can I contact Bio-Rad Laboratories, Inc. Class A Common Stock?

Bio-Rad Laboratories, Inc. Class A Common Stock's mailing address is 1000 ALFRED NOBEL DR, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories, Inc. Class A Common Stock (BIO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  434
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories, Inc. Class A Common Stock and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.